VBI Vaccines — Investor Presentation (November 2017)
35 slides from VBI Vaccines's investor presentation, Nov 28, 2017
Slide 1: VBI Vaccines November 2017
iy ©} VBI VACCINES CORES os NASDAQ: VBIV TSX: VBV x NOVEMBER 2017
Slide 2: Cautionary Statement Regarding Forward-Looking Information
Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 an
Slide 3: 1. Introduction to VBI Vaccines
= 1. Introduction to VBI Vaccines wr, ie evbiz na NASDAQ: VBIV | TSX: VBV 3
Slide 4: VBI Vaccines Global Footprint
OOOO eee VBI Vaccines Global Footprint aan é it 2 eae i HEADQUARTERS — CAMBRIDGE, MA = CEO,CSO, EBO:+..3 FTES: =" Central location in biotechnology hub RESEARCH OPERATIONS — OTTAWA, CANADA = CMO, Finance + “25 FTEs =" World-class R&D team and facility MANUFACTURING FACILITY — REHOVOT, ISRAEL = ~65 F
Slide 5: VBI Vaccines Leadership
VBI Vaccines Leadership MANAGEMENT ian ee Jeff Baxter y 4) c UMN Dr. Francisco Diaz-Mitoma, M.D., Ph.D. President & CEO gasmithtine GROUP " Chief Medical Officer AMRIC ¢ Dr. David Anderson, Ph.D. HARVARD’ Nell Beattie ARTISAN Chief Scientific Officer NEON Chief Business Officer ‘a SUR Seraol-st Racy
Slide 6: Leading Immunology Innovation in Significant Markets with High Unmet Need
Leading Immunology Innovation in Significant Markets with High Unmet Need TECHNOLOGY PLATFORMS * Enveloped Virus-Like Particle (“eVLP”) and durable immune responses * Lipid Particle Vaccine (“LPV™”) Platform enables thermostable delivery, and increased access, safety, and efficacy Broad research col
Slide 7: VBI Vaccines Pipeline
VBI Vaccines Pipeline Multiple Opportunities in Infectious Disease and Oncology LEAD PRE-CLINICAL PHASE! PHASE Il = PHASE IIl_ APPROVED STATUS INFECTIOUS DISEASE = Initiation of global Ph IIL Sci-B-Vac® (Hepatitis B) prea cyotied (Licensed in 15 countries) Q4 2017 cytomegalovirus (cw) [NN Zika Final
Slide 8: Recent Key Achievements
Recent Key Achievements JUNE 2016 —- NOVEMBER 2017 November 2017 Appointment of Ran Nussbaum, of Pontifax, to Board of Directors October 2017 Closed Public Offering and concurrent Registered Direct Offering for aggregate proceeds of $71.9MM August 2017 FDA acceptance of IND and receipt of Health Can
Slide 9: 2. Sci-B-Vac: Hepatitis B
tll, "42 vbiz = 2. Sci-B-Vac®: Hepatitis B MY Zim ° evbig bel NASDAQ; VBIV | TSX: VBV 9
Slide 10: Hepatitis B Unmet Need
OOOO eee Hepatitis B Unmet Need Reported US H Coverage — 2015 (23 doses) Otherwise Healthy Adults aged 2 19 years 24.6% Adults aged 19-49 years 32.0% Adults age 2 50 years 16.5% High-Risk Chronic Liver Conditions 27.4% Diabetics — Age 19-59 years 24.4% Diabetics — Age > 60 years 12.6% Healthcare Pro
Slide 11: Existing High Unmet Need in Specific Populations
OOOO eee Existing High Unmet Need in Specific Populations SEROCONVERSION RATES WITH CURRENT VACCINES FALL DRAMATICALLY WITHIN THE ELDERLY AND HIGH-RISK PATIENT POPULATIONS Anti-HBs Seroconversion Rates After Hepatitis B Vaccination Neonates > 95% Age 2-19 ~99% Age 20 - 29 ~95% Age 30 - 39 ~90% Age 4
Slide 12: Sci-B-Vac Overview
Sci-B-Vac® Overview ONLY COMMERCIAL HBV VACCINE KNOWN TO MIMIC ALL THREE VIRAL SURFACE ANTIGENS — ALREADY SAFELY USED IN 500,000+ PATIENTS * Sci-B-Vac® achieves rapid onset of protection, with high levels of anti-HBV antibodies (HBsAb), at a lower dosage than competing vaccines 2% GENERATION VACCINE
Slide 13: Sci-B-Vac Existing Safety and Efficacy Data Package
OOOO eee Sci-B-Vac® Existing Safety and Efficacy Data Package EXTENSIVE CLINICAL DEVELOPMENT SUPPORTS PHASE III DESIGN Voi. Product distribution data globally estimates that over 500,000 infants and adults have been vaccinated with Sci-B-Vac® In the last two decades, 22 clinical trials have been com
Slide 14: Sci-B-Vac Demonstrated Superior Seroprotection Rates in Older Adults
Sci-B-Vac® Demonstrated Superior Seroprotection Rates in Older Adults Stratification by Age of Study 38-96-040 Demonstrates Significantly Improved Potency in Older Adults Seroprotection Stratified by Age — Percent HBsAg Seropr ee ge 2aa0 peg RRR \ << 55.0% | 50.0% Engerix B <= 45 (n = 136) Engerix B
Slide 15: Interim Data from Israeli Phase IV Study
Interim Data from Israeli Phase IV Study Reinforces Strength of Sci- B-Vac® Potency in Adult Populations & Potential for Rapid Seroprotection 100% 80% 60% 40% 20% 0% SCI-B-VAC® PHASE IV STUDY IN ISRAELI ADULTS (AGE 18-40, N=88) SEROPROTECTION (>10 IU/ML) 98.8% 91.9% 56.8% Month 1 Month 2 Month 3 30-
Slide 16: Proposed Phase III Clinical Program
OOOO eee Proposed Phase III Clinical Program Voi. Target Population: ~4,800 adults age 18 years and older Expected Duration: 15 Months Clinical Trial Sites: ~40 sites across the US, Europe, and Canada Design: Two concurrent Phase Ill studies: 1. PROTECT : Safety and immunogenicity study (n=1,600) 2.
Slide 17: 3. eVLP Portfolio Programs
3. eVLP Portfolio Programs Z S 7TMS ie evbiz na NASDAQ: VBIV | TSX: VBV v7
Slide 18: eVLPs are a 3rd-Generation Class of Synthetic Vaccines
OOOO eee eVLPs are a 3'-Generation Class of Synthetic Vaccines = eVLPs are the same size and structure as enveloped viruses; present antigens in their natural state for an improved immune response = The foundation of the eVLP Platform is a stable, protein-based core on which additional vaccine antig
Slide 19: 3a. CMV
3. eVLP Portfolio Programs a. CMV ie evbiz na NASDAQ: VBIV | TSX: VBV 19
Slide 20: Congenital CMV is a Leading Public Health Priority
Congenital CMV is a Leading Public Health Priority U.S. CHILDREN BORN WITH OR DEVELOPING LONG-TERM MEDICAL CONDITIONS Congenital CMV Disease Fetal Alcohol Syndrome Down Syndrome Spina Bifida / Anencephaly Pediatric HIV / AIDS Invasive Hib than Down Syndrome CMV affects more live births or Fetal Alco
Slide 21: Congenital CMV is a Leading Public Health Priority
OOOO eee Congenital CMV is a Leading Public Health Priority = Each year, approximately 30,000 infants are born each year with CMV infection, of which 5,000+ U.S. infants will develop permanent problems including deafness, blindness, and developmental delays = Inthe U.S., the direct economic costs of
Slide 22: eVLP Presentation Improves CMV Vaccine Potency
eVLP Presentation Improves CMV Vaccine Potency Presentation of gB antigen in an eVLP improves relevant functional CMV neutralizing responses relative to recombinant gB protein PRECLINICAL RESULTS Neutralizing antibody titers for mice immunized _ : : with comparable doses of Recombinant gB of * Neutr
Slide 23: CMV Phase I Clinical Trial Overview
CMV Phase | Clinical Trial Overview Opportunity for Immunologic Human Proof of Concept with Ph | Data TRIAL DESIGN * Target Population: 128 CMV-Negative Healthy Adults (18-40 yrs) * Design: Staggered Enrollment with Vaccinations at 0, 2, and 6 Months ¢ Duration: 20 Months * Interim Data Read-Out: Ba
Slide 24: Interim Phase I Immunogenicity Signals (1)
Interim Phase | Immunogenicity Signals (1) BASED ON SUBJECT SAMPLES COLLECTED 1 MONTH AFTER 2ND VACCINATION After two vaccinations, immunization of subjects with the highest dose of VBI-1501A (2.0ug) induced: * Seroconversion* in 100% of subjects + Adjuvant (alum) enhances immunogenicity * Neutraliz
Slide 25: Interim Phase I Immunogenicity Signals (2)
Interim Phase | Immunogenicity Signals (2) BASED ON SUBJECT SAMPLES COLLECTED 1 MONTH AFTER 2ND VACCINATION Clear dose-dependent boosting of response: 25 o 4 20: Fold-increase is based on comparison 2 15 of antibody binding GMTs at 2 day 56 (post 1% vaccination) vs. ac 10: day 84 (1 month post 2” va
Slide 26: Interim Phase I Data Summary
OOOO eee Interim Phase | Data Summary * \VBI-1501A is safe and well tolerated at all doses tested ¢ VBI-1501A is immunogenic after 2 doses Evidence of strong boosting in antibody titers observed, which is dose-dependent Observed neutralizing antibodies against epithelial cell infection in some subje
Slide 27: 3b. GBM
3. eVLP Portfolio Programs b. GBM SS TTS ie evbiz na NASDAQ: VBIV | TSX: VBV 27
Slide 28: Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate
Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate (VBI-1501A) by Adding an Internal pp65 Protein to Elicit a Th1 Response Attributes gB Envelope pp65 ‘Foreign’ ‘Foreign’ Viral Antigen y Viral Antigen Bivalent — pp65 for Therapeutic Immuno- Oncology Monovalent gB for Prophylaxis Present
Slide 29: Poor Immunogenicity of Traditional Tumor-Associated Antigens
Poor Immunogenicity of Traditional Tumor-Associated Antigens (TAAs) has Limited Past Therapeutic Cancer Vaccines IMMUNOGENICITY LOW HIGH VIRAL CMV ANTIGENS ARE OVER-EXPRESSED (>90%) IN MULTIPLE SOLID TUMORS, INCLUDING: * Glioblastoma (GBM)! * Medulloblastoma?? * Meningioma? ¢ Breast ca ncer*> Source
Slide 30: VBI-1901: Re-stimulated CD4+ and CD8+ T-cell Responses
VBI-1901: Re-stimulated CD4+ and CD8+ T-cell Responses in CMV-positive Human Subject Ex Vivo Restimulation of CD4+ & CD8+ T-cells in ¢ Fresh PBMCs stimulated Ex Vivo Human Samples with VBI-1901 vs = CD4*IFN-y* CD8*IFN-+ recombinant antigens % 10 25 4 * eVLPs rapidly restimulate a hal 2.0 ° both CD4+
Slide 31: VBI-1901 Induction of CCL3 in Ex Vivo PBMCs
VBI-1901 Induction of CCL3 in Ex Vivo PBMCs from CMV-positive Healthy Subjects and Patients with Solid Tumors CCL3 Secretion = @ D 2§ 15 a fis = ° $ 2 8 P=] @ = 10 2 eo °° io) = o e 9 SR Ss 3 26 rs) oe e aS o r3 3 a s S oe Ss fe) * PBMCs from CMV+ healthy subjects or patients with GBM, medulloblasto
Slide 32: VBI GBM Candidate Expected Timeline
OOOO eee VBI GBM Candidate Expected Timeline COMPLETED MILESTONES v Q1 2016: Pre-clinical IND-enabling data Y Q1 2016: Clinical Advisory Meeting v Q2 2016: Pre-IND meeting with FDA v Q1 2017: GMP clinical trial materials manufactured v Q3 2017: IND accepted for Phase I/Ila clinical study REMAINING M
Slide 33: 4. Summary
CWP G, MZ < o. 4. Summary \\ \\ Ze Z S SN TTS bel NASDAQ; VBIV | TSX: VBV 33
Slide 34: Value Proposition for VBI Vaccines
ee Value Proposition for VBI Vaccines KEY VALUE DRIVERS IN NEXT 18 MONTHS: Sci-B-Vac®: Phase III Program in the U.S., Europe, and Canada Initiation of enrollment exp. in Q4 2017, headline results expected H1 2019 CMV: Phase | Clinical Study Final results expected H1 2018 GBM: Phase I/Ila Clinical St
Slide 35: VBI Vaccines contact details
\N D S LZ VOI. Wy, ws VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com NASDAQ: VBIV | TSX: VB\